Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Boston Scientific releases clinical outcomes data for Taxus Liberte stent

Boston Scientific : 02 September, 2008  (Company News)
Boston Scientific has released one-year results from the European and Intercontinental launch phases of its global Taxus OLYMPIA registry, the world's largest post-approval, prospective registry for a single drug-eluting stent (DES).
Results from the 22,000-patient study were presented by Oscar Mendiz, MD, at the European Society of Cardiology Congress in Munich, Germany.

OLYMPIA is designed to analyse real-world clinical outcomes data for Boston Scientific's second-generation Taxus Liberte Paclitaxel-Eluting Coronary Stent System in the treatment of patients with coronary artery disease.

The Taxus OLYMPIA registry employs a consecutive enrollment process and consists of diverse and high-risk patient populations, reflecting real-world usage patterns found in everyday clinical practice. One-year data were collected for a total of 22,345 patients to date in 57 countries. A large majority of patients (75 percent) were considered 'expanded use' cases consisting of complex lesions or complex clinical characteristics. The overall OLYMPIA population in these two phases included patients with multivessel disease (56.5 percent), prior PCI (27.9 percent), prior myocardial infarction (MI) (34.1 percent), multiple stents (32.3 percent), and medically treated diabetes (27.0 percent).

The one-year results demonstrated a low overall 3.8 percent rate of Taxus Liberte stent-related composite cardiac events, including cardiac death (1.2 percent), MI (0.8 percent), and re-intervention (TLR) (2.5 percent). The definite Stent thrombosis rate was 0.8 percent after one year, which is consistent with safety data from other DES registries. In the more complex expanded use patient population, the rates of stent-related composite cardiac events and Stent thrombosis were 4.3 percent and 0.9 percent respectively. The Taxus Liberte Stent also exhibited a high degree of procedural success at 99.7 percent.

'The Taxus OLYMPIA registry shows impressive results in the largest, prospective DES patient population ever studied for an individual stent,' said Dr Mendiz, Fundacion Favaloro, Buenos Aires, Argentina. 'The low occurrence of cardiac events and Stent thrombosis is noteworthy, especially given the high degree of complex patients and lesions from real-world practice in this study.'

In the medically treated diabetic subset of 5,692 patients, OLYMPIA reported a 4.6 percent rate of overall Taxus Liberte stent-related cardiac events and 0.8 percent definite Stent thrombosis. The diabetic patient subset is typically considered to be at high risk for adverse events associated with bare-metal stenting.

'The one-year OLYMPIA results reinforce the success of the Taxus Liberte Stent in effectively treating a wide-range of patients routinely seen in the cath lab,' said Donald S. Baim, MD, chief medical and scientific officer of Boston Scientific. 'This second-generation platform offers exceptional deliverability and a Stent geometry designed specifically for drug elution.'

The Taxus Liberte Stent is currently pending approval by the US Food and Drug Administration and is not available for sale in the USA.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo